Consumer medicine information

Comirnaty COVID-19 Vaccine

Tozinameran

BRAND INFORMATION

Brand name

Comirnaty

Active ingredient

Tozinameran

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Comirnaty COVID-19 Vaccine.

COMIRNATY® COVID-19 VACCINE

COMIRNATY® COVID-19 VACCINE


 Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about receiving this vaccine, speak to your doctor or pharmacist.


 This vaccine is new or being used differently. Please report side effects. See the full CMI for further details.
 1. Why am I being given COMIRNATY?

COMIRNATY is a vaccine given to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults and adolescents from 12 years of age and older. COMIRNATY contains the active ingredient tozinameran. For more information, see Section 1. Why am I being given COMIRNATY? in the full CMI.

 2. What should I know before I am given COMIRNATY?

You should not be given COMIRNATY if you've had an allergic reaction to any of the ingredients in COMIRNATY. See list at the end of the CMI. Check with your doctor if you've had: a severe allergic reaction or breathing problems after any other vaccine or after being given COMIRNATY in the past; fainted after any needle injection; a severe illness or infection with high fever; a weakened immune system or are on a medicine that affects your immune system; a bleeding disorder, bruise easily or are on blood thinners. As with any vaccine, COMIRNATY may not fully protect all who receive it and it is not known how long you'll be protected. Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. COMIRNATY should not be given to children under 12 years. For more information, see Section 2. What should I know before I am given COMIRNATY? in the full CMI.

 3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription. Tell your doctor or pharmacist if you have recently received any other vaccine. For more information, see Section 3. What if I am taking other medicines? in the full CMI.

 4. How will I be given COMIRNATY?

COMIRNATY will be given as an injection into the muscle of your upper arm by a doctor, nurse or pharmacist. You will be given one dose followed by a second dose at least 21 days later. It is very important that you receive your second dose. If you are immunocompromised, you may receive a third dose of Comirnaty at least 28 days after the second dose as part of the primary vaccination. You may receive a booster dose at least 6 months after the primary vaccination and a subsequent booster at least 4 months after a previous booster. For more information, see Section 4. How will I be given COMIRNATY? in the full CMI.

 5. What should I know while being given COMIRNATY?

Things you should know
  • If you receive one dose of COMIRNATY, you should receive a second dose of the same vaccine 21 days later to complete the primary vaccination schedule. If you are immunocompromised, you may receive a third dose of Comirnaty at least 28 days after the second dose as part of the primary vaccination.
  • A booster dose of COMIRNATY may be given at least 6 months after the primary vaccination for people 12 years of age and older.
  • A subsequent booster dose of COMIRNATY may be given at least 4 months after a previous booster
  • You may not be protected against COVID-19 disease until at least seven days after your second dose.
  • You may not be protected if you only receive one dose, so a second dose is important.
Driving or using machines
  • Be careful before you drive or use any machines or tools until you know how COMIRNATY affects you. Some of the side effects of COMIRNATY may temporarily affect your ability to drive or use machines.

For more information, see Section 5. What should I know while being given COMIRNATY? in the full CMI.

 6. Are there any side effects?

Very common side effects of COMIRNATY include pain/swelling at injection site, tiredness, headache, muscle pain, chills, joint pain and fever. For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.


 This vaccine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

COMIRNATY® COVID-19 VACCINE

Active ingredient: tozinameran


 Consumer Medicine Information (CMI)

This leaflet provides important information about using COMIRNATY. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about receiving COMIRNATY.

Where to find information in this leaflet:

1. Why am I being given COMIRNATY?
2. What should I know before I am given COMIRNATY?
3. What if I am taking other medicines?
4. How will I be given COMIRNATY?
5. What should I know while being given COMIRNATY?
6. Are there any side effects?
7. Product details

1. Why am I being given COMIRNATY?

COMIRNATY contains the active ingredient tozinameran. COMIRNATY is an mRNA (messenger ribonucleic acid) vaccine.

COMIRNATY is a vaccine given to prevent COVID-19 disease caused by SARS-CoV-2 virus in adults and adolescents from 12 years of age and older.

COMIRNATY works by triggering your immune system to produce antibodies and blood cells that work against the virus, to protect against COVID-19 disease.

2. What should I know before I am given COMIRNATY?

Warnings

COMIRNATY should not be given:

  1. if you are allergic to tozinameran or any of the ingredients listed at the end of this leaflet.

Check with your doctor if you have:

  • had a severe allergic reaction or breathing problems after any other vaccine or after being given COMIRNATY in the past.
  • fainted following any needle injection.
  • a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.
  • a weakened immune system, such as due to HIV infection or are on a medicine that affects your immune system.
  • a bleeding disorder, bruise easily or are on a blood thinning medicine.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Very rare cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have been reported after vaccination with COMIRNATY. The cases have mostly occurred within two weeks following vaccination, more often after the second vaccination, and more often, but not always, in younger men. There have been cases in women. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur. Sometimes the symptoms of myocarditis and pericarditis may not be specific and could include tiredness, dizziness, nausea and vomiting, abdominal pain, swelling, and cough.

You may develop a temporary, stress-related response associated with the process of receiving your injection. This may include dizziness, fainting, sweating, increased heart rate and/or anxiety. If you start to feel faint at any time during the process of receiving your injection, let your doctor, nurse or pharmacist know and take actions to avoid falling and injuring yourself, such as sitting or lying down.

As with any vaccine, COMIRNATY may not fully protect all those who receive it and it is not known how long you will be protected.

Pregnancy and breastfeeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you receive this vaccine.

Children and adolescents

COMIRNATY should not be given to children under 12 years.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Tell your doctor or pharmacist if you have recently received any other vaccine.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect, or are affected by, COMIRNATY.

4. How will I be given COMIRNATY?
  • COMIRNATY will be given as an injection into the muscle of your upper arm by a doctor, nurse or pharmacist.
  • For primary vaccination, you will be given two doses. One dose followed by a second dose at least 21 days later. If you miss the second dose, ask your doctor for advice.
  • If you are immunocompromised, you may receive a third dose of Comirnaty at least 28 days after the second dose as part of the primary vaccination.
  • A doctor, nurse or pharmacist will observe you for at least 15 minutes after being given COMIRNATY.
  • A booster dose of COMIRNATY may be given at least 6 months after the primary vaccination for people 12 years of age and older.
  • A subsequent booster of COMIRNATY may be given at least 4 months after a previous booster.
5. What should I know while being given COMIRNATY?

Things you should know

  • If you receive one dose of COMIRNATY, you should receive a second dose of the same vaccine at least 21 days later to complete the primary vaccination schedule.
  • If you are immunocompromised, you may receive a third dose of Comirnaty at least 28 days after the second dose as part of the primary vaccination.
  • A booster dose of COMIRNATY may be given at least 6 months after the primary vaccination for people 12 years of age and older.
  • You may not be protected against COVID-19 disease until at least seven days after your second dose.
  • You may not be protected if you only receive one dose, so a second dose is important.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how COMIRNATY affects you.

Some of the side effects of COMIRNATY may temporarily affect your ability to drive or use machines.

Storage of the vaccine

COMIRNATY is stored at -90°C to -60°C. It must be kept in the original package in order to protect from light.

A doctor, nurse or pharmacist will prepare the injection for you before you are given it.

Getting rid of any unwanted vaccine

A doctor, nurse or pharmacist will dispose of any unused vaccine.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Very common side effects

Very common side effectsWhat to do
  • pain/swelling at injection site
  • tiredness
  • headache
  • muscle pain
  • chills
  • joint pain
  • fever
Speak to your doctor if you have any of these very common side effects and they worry you.

Common side effects

Common side effectsWhat to do
  • redness at injection site
  • nausea
Speak to your doctor if you have any of these common side effects and they worry you.

Uncommon side effects

Uncommon side effectsWhat to do
  • enlarged lymph nodes
  • feeling unwell
  • arm pain
  • insomnia
  • decreased appetite
  • excessive sweating
  • night sweats
  • physical weakness and/or lack of energy
Speak to your doctor if you have any of these side effects and they worry you.

Rare side effects

Rare side effectsWhat to do
  • temporary one-sided facial drooping
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice this side effect.

Other side effects (frequency unknown)

Other side effects (frequency unknown)What to do
  • severe allergic reaction
  • allergic reactions such as rash, itching, hives or swelling of the face
  • inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in chest pain, breathlessness and/or palpitations
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.
  • diarrhoea
  • vomiting
  • pain in arm
  • extensive swelling of vaccinated arm
  • swelling of face (people who have had facial dermal fillers)
  • unusual sensation (e.g. tingling or pricking, “pins-and-needles”)
  • numbness
  • skin lesions (bull's-eye-shaped)
  • dizziness
  • genital ulcers
  • heavy menstrual (period) bleeding
Speak to your doctor if you have any of these side effects and they worry you.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this vaccine.

7. Product details

What COMIRNATY contains

Active ingredient
(main ingredient)
  • tozinameran
Other ingredients
(inactive ingredients)
  • ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)
  • 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)
  • Distearoylphosphatidylcholine (DSPC)
  • Cholesterol
  • Potassium chloride
  • Monobasic potassium phosphate
  • Sodium chloride
  • Dibasic sodium phosphate dihydrate
  • Sucrose
  • Water for injections

Do not receive this vaccine if you are allergic to any of these ingredients.

What COMIRNATY looks like

COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial.

After dilution, each vial contains 6 doses of vaccine.

AUST R 346290.

Who distributes COMIRNATY

Pfizer Australia Pty Ltd
Sydney NSW
Toll Free Number: 1800 675 229
www.pfizermedinfo.com.au

COMIRNATY® is a registered trademark of BioNTech SE. Used under license.

This leaflet was prepared in September 2023.

© Copyright

Published by MIMS October 2023

BRAND INFORMATION

Brand name

Comirnaty

Active ingredient

Tozinameran

Schedule

S4

 

1 Name of Medicine

Tozinameran.

2 Qualitative and Quantitative Composition

This is a multidose vial and must be diluted before use.
One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution, see Section 4.2 Dose and Method of Administration.
1 dose (0.3 mL) contains 30 microgram of tozinameran (embedded in lipid nanoparticles).
The active ingredient is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Concentrated suspension for injection (sterile concentrate).
Comirnaty is a white to off-white frozen suspension.

4 Clinical Particulars

4.9 Overdose

Overdose data is available from 52 study participants included in the clinical trial that due to an error in dilution received 58 microgram of Comirnaty. The Comirnaty recipients did not report an increase in reactogenicity or adverse reactions.
In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity/carcinogenicity. Neither genotoxicity nor carcinogenicity studies were performed. The components of Comirnaty (lipids and mRNA) are not expected to have genotoxic potential.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

CAS number. 2417899-77-3.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/COMIRNST.gif